Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
September 18, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
Aprea Therapeutics to Present at Upcoming Investor Conferences
September 03, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
August 11, 2020 16:15 ET
|
Aprea Therapeutics
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
July 16, 2020 07:00 ET
|
Aprea Therapeutics
Commenced expansion cohort in combination with venetoclax and azacitidineAdded cohort to be activated in combination with azacitidine BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics,...
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
June 29, 2020 07:00 ET
|
Aprea Therapeutics
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
June 12, 2020 06:00 ET
|
Aprea Therapeutics
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
June 03, 2020 08:00 ET
|
Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
May 18, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
May 15, 2020 07:30 ET
|
Aprea Therapeutics
BOSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Launches New Corporate Website - www.aprea.com
April 06, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...